The JAK-STAT pathway is a potential target for treatment of pediatric kidney tumors and research efforts have been aimed at understanding mechanisms of resistance to immunotherapy and how anti-tumor immune response can be therapeutically enhanced. This evidence concerns the gene SOAT1 and kidney neoplasm.